Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Open accessThe DOI matches its Crossref record; 275 of the 279 references it cites were found in a registry or an index.
Abstract
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are two incretins that bind to their respective receptors and activate the downstream signaling in various tissues and organs. Both GIP and GLP-1 play roles in regulating food intake by stimulating neurons in the brain’s satiety center. They also stimulate insulin secretion in pancreatic β-cells, but their effects on glucagon production in pancreatic α-cells differ, with GIP having a glucagonotropic effect during hypoglycemia and GLP-1 exhibiting glucagonostatic effect during hyperglycemia. Additionally, GIP directly stimulates lipogenesis, while GLP-1 indirectly promotes lipolysis, collectively maintaining healthy adipocytes, reducing ectopic fat distribution, and increasing the production and secretion of adiponectin from adipocytes. Together, these two incretins contribute to metabolic homeostasis, preventing both hyperglycemia and hypoglycemia, mitigating dyslipidemia, and reducing the risk of cardiovascular diseases in individuals with type 2 diabetes and obesity. Several GLP-1 and dual GIP/GLP-1 receptor agonists have been developed to harness these pharmacological effects in the treatment of type 2 diabetes, with some demonstrating robust effectiveness in weight management and prevention of cardiovascular diseases. Elucidating the underlying cellular and molecular mechanisms could potentially usher in the development of new generations of incretin mimetics with enhanced efficacy and fewer adverse effects. The treatment guidelines are evolving based on clinical trial outcomes, shaping the management of metabolic and cardiovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Physiological and Pharmacological Effects of GIP, GLP-1 and Their Receptor Agonists. (A) GIP and GLP-1 secretion. Enteroendocrine K cells in the upper gastrointestinal tract (duodenum and jejunum) and L cells in the distal gut (ileum and colon) produce and secret GIP and GLP-1, respectively, into the circulation. GIP peptide and the downstream signaling pathways are depicted in blue, while GLP-1 peptide and the downstream signaling pathways are represented in red. The signaling pathways regulated by both GIP and GLP-1 are shown in violet. (B) Effects on pancreatic endocrine functions. Both GIP and GLP-1 have insulinotropic effects on pancreatic β-cells during hyperglycemia. GIP has a glucagonotropic effect in pancreatic α-cells during hypoglycemia but no effect during hyperglycemia. GLP-1 has an indirect glucagonostatic effect during hyperglycemia but no effect during hypoglycemia. (C) Effects in the brain. Both GIP and GLP-1 activate their respective receptors in distinct neurons within central nervous system (e.g., hypothalamus) to increase the sense of satiety. Notably, GLP-1, but not GIP, is directly produced in the brain (e.g., nucleus of the solitary tract (NST) and hypothalamus), but both hormones can cross blood-brain barrier from systemic circulation. The central nervous system [e.g., rostral ventrolateral medulla (RVLM)] transmits GLP-1 signaling to increase sympathetic tone, which in turn enhances lipolysis in adipose tissue. The central nervous system (e.g., NST) also relays GLP-1 signaling between afferent and efferent vagal nerves to delay gastric emptying. (D) Effects on the stomach. GLP-1delays the gastric emptying, thereby reducing the postprandial lipid and carbohydrate surges. This effect of GLP-1 is at least partially mediated by the neuronal pathway, including afferent vagal nerve, brainstem (e.g., NST), and efferent vagal nerve. GIP does not have a similar mechanism for regulating gastric emptying. (E) Effects on adipose tissue and liver. GIP binds GIPR in adipose tissue and activates a signaling cascade that increases lipoprotein lipase (LPL) expression and secretion. LPL enhances triglyceride (TG) clearance from circulation, facilitates the transport of TG to adipocytes for lipogenesis, and attenuates ectopic fat accumulation in visceral organs. GLP-1 indirectly enhances lipolysis via increased sympathetic activity through the central nervous system. Both GIP and GLP-1 have indirect effects on the liver by increasing the secretion of adiponectin from adipose tissue and attenuating hypertriglyceridemia. These mechanisms reduce hepatic fat accumulation, ameliorate insulin resistance, and inhibits hepatic glucogenesis.](https://figures.cochat.ai/paper-figures/231ad048d31c4cf5bd774e92003aa582/mechanisms-of-action-and-therapeutic-applications-of-glp-1-and-dual-gip-glp-1-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, GLP-1 inhibits gastric emptying and reduces bowel motility through a vagally mediated gastric braking mechanism [29,30].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, GLP-1 enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from alpha cells, thereby reducing hepatic glucose output [29,30].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Therapeutic GLP-1 RAs are resistant to this enzymatic degradation, providing supraphysiological levels of receptor activation over extended periods [29,30].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“…lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT…”
BackgroundOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“…of the postprandial insulin responses in healthy individuals and may be substantially reduced to 20% – 30% in individuals with type 2 diabetes mellitus (T2DM) (6, 7), a complex disorder arising from inadequate compensation of insulin secretion by pancreas to counter peripheral insulin resistance.”
BackgroundWeyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Research works printed but not linked: 1
- 2020, Rybelsus prescribing information
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
“39”
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 53
Movahednasab, M., Dianat‐Moghadam, H., Khodadad, S., Nedaeinia, R., Safabakhsh, S., Ferns, G. A., & Salehi, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01623-w · Cited by 46
Urkon, M., Ferencz, E., Szász, J. A., Szabó, M. I. M., Orbán-Kis, K., Szatmári, S., & Nagy, E. E. (2025) · Pharmaceuticals · doi:10.3390/ph18050614 · Cited by 44
“Therefore, unimolecular dual GLP-1/GIP receptor agonists have been developed and clinically tested for the management of T2DM and obesity [124,125].”
Metadata
- Authors
- Liu, Q. K.
- Affiliations
- Montgomery General Hospital (US)
- Corresponding author
- Liu, Qiyuan Keith
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2024-07-24
- Volume
- 15
- Pages
- 1431292-1431292
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC11304055
- OpenAlex
- W4400956092
- Cited by
- 265
- References
- 279
- Citations by year
- 2026: 156 · 2025: 107 · 2024: 2
- FWCI
- 15.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, GIP/GLP-1 receptor agonist, incretin mimetics, type 2 diabetes, obesity, insulin secretion, satiety, lipogenesis, lipolysis, adiponectin, cardiovascular disease prevention, weight management, dyslipidemia, metabolic homeostasis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Receptors, Gastrointestinal Hormone, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. https://app.cochat.ai/papers/10.3389/fendo.2024.1431292
- The paper
- Liu, Q. K. (2024). Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2024.1431292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.